MC1R raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
The process for class 1 inteins begins with an N-O or N-S shift when the side chain of the first residue (a serine, threonine, or cysteine) of the intein portion of the precursor protein nucleophilically attacks the peptide bond of the residue immediately upstream (that is, the final residue of the N-extein) to form a linear ester (or thioester) intermediate. A transesterification occurs when the side chain of the first residue of the C-extein attacks the newly formed (thio)ester to free the N-terminal end of the intein. This forms a branched intermediate in which the N-extein and C-extein are attached, albeit not through a peptide bond. The last residue of the intein is always an asparagine (Asn), and the amide nitrogen atom of this side chain cleaves apart the peptide bond between the intein and the C-extein, resulting in a free intein segment with a terminal cyclic imide. Finally, the free amino group of the C-extein now attacks the (thio)ester linking the N- and C-exteins together. An O-N or S-N shift produces a peptide bond and the functional, ligated protein. Class 2 inteins have no nucleophilic first side chain, only an alanine. Instead, the reaction starts directly with a nucleophilic displacement, with the first residue of the C-extein attacking the peptide carboxyl on the final residue of the N-extein. The rest proceeds as usual, starting with Asn turning into a cyclic imide. Class 3 inteins have no nucleophilic first side chain, only an alanine, yet they have an internal noncontiguous "WCT" motif.
Psilocybin is a naturally occurring substituted tryptamine that features an indole ring linked to an aminoethyl substituent. It is structurally related to serotonin, a monoamine neurotransmitter that is a derivative of the amino acid tryptophan. Psilocybin is a member of the general class of tryptophan-based compounds that originally functioned as antioxidants in earlier life forms before assuming more complex functions in multicellular organisms, including humans. Other related indole-containing psychedelic compounds include dimethyltryptamine, found in many plant species and in trace amounts in some mammals, and bufotenin, found in the skin of certain amphibians, especially the Colorado River toad. Psilocybin is a white, crystalline solid that is soluble in water, methanol and ethanol but insoluble in nonpolar organic solvents such as chloroform and petroleum ether. It has a melting point between 220 and 228 °C (428 and 442 °F), and an ammonia-like taste. Its pKa values are estimated to be 1.3 and 6.5 for the two successive phosphate hydroxy groups and 10.4 for the dimethylamine nitrogen, so it typically exists as a zwitterionic structure. There are two known crystalline polymorphs of psilocybin, as well as reported hydrated phases. Psilocybin rapidly oxidizes upon exposure to light—an important consideration when using it as an analytical standard.
==== Physiological effects ==== Angiotensin II exhibits endocrine, autocrine/paracrine, and intracrine functions. It promotes aldosterone release from the adrenal cortex, as well as arginine vasopressin release from the posterior pituitary. It acts directly upon the proximal tubules of the kidney to regulate water and Na+ reabsorption, promoting reabsorption at very low concentrations while increasingly inhibiting reabsorption with increasing concentrations. In the proximal tubule, it promotes Na+ reabsorption and H+ excretion (which is coupled to bicarbonate reabsorption) by the Na+/H+ exchanger. It causes venous and arterial vasoconstriction by a Gq alpha subunit-coupled receptor upon vascular smooth muscle cells (with downstream IP3-dependent mechanism causing a rise in intracellular Ca2+ to effect smooth muscle excitation-contraction coupling), thus acting to increase blood pressure.
=== Corporate self-regulation === AI labs and companies generally abide by safety practices and norms that fall outside of formal legislation. One aim of governance researchers is to shape these norms. Examples of safety recommendations found in the literature include performing third-party auditing, offering bounties for finding failures, sharing AI incidents (an AI incident database was created for this purpose), following guidelines to determine whether to publish research or models, and improving information and cyber security in AI labs. Companies have also made commitments. Cohere, OpenAI, and AI21 proposed and agreed on "best practices for deploying language models", focusing on mitigating misuse. To avoid contributing to racing-dynamics, OpenAI has also stated in their charter that "if a value-aligned, safety-conscious project comes close to building AGI before we do, we commit to stop competing with and start assisting this project" Also, industry leaders such as CEO of DeepMind Demis Hassabis, director of Facebook AI Yann LeCun have signed open letters such as the Asilomar Principles and the Autonomous Weapons Open Letter.
This method can be used to investigate protein-protein interactions, as well as to investigate modulators of protein-protein interactions by assessing ternary complex formation. An example for such modulators are PROTACs, which are investigated for their therapeutic potential in cancer therapy. Another example for such ternary interactions are bispecific antibodies binding to their two distinct antigens. switchSENSE can additionally be utilized to detect conformational changes induced by ligands binding to a target protein.
Sources: en.wikipedia.org
Mass media, lawmakers, and Donald Trump raised concerns about Biden's age, including his cognitive state, during and after the 2020 United States presidential election. According to a February 2024 poll, Biden's age and health were major or moderate concerns for 86% of voters generally, up from 76% in 2020. According to another February 2024 poll, most of those who voted for Biden in 2020 believed he was too old to be an effective president; The New York Times noted that these concerns "cut across generations, gender, race and education". Concerns about Biden's age and health increased after a poor performance by Biden during a debate against Trump in June 2024. That performance led a number of commentators and Democratic lawmakers to call for Biden to drop out of the 2024 presidential race. In July 2024, Biden ultimately withdrew from the race while stating that he would continue serving as president until the conclusion of his term.
== Fossils of the Ediacaran == For more information, see Ediacaran biota. The fossils found that date back to the Precambrian lack distinct structures since there were no skeletal forms during this period. Skeletons did not arise until the Cambrian Period when oxygen levels increased. This is because skeletons require collagen, which uses Vitamin C as a cofactor, which requires oxygen. For more information on the rise of oxygen see the section on oxygen. The majority of fossils from this Era come from either Mistaken Point on the East Coast of Canada or the Ediacara Hills in Southern Australia. Most of the fossils are found as impressions of soft-bodied organisms in the shape of disks, ribbons or fronds. There are also trace fossils that provide evidence that some of these Precambrian organisms were most-likely worm-like creatures that were locomotive. Most of these fossils lack any recognizable heads, mouths or digestive organs, and are thought to have fed via absorptive mechanisms and symbiotic relationships with chemoautotrophs (Chemotroph), photoautotrophs (Phototroph) or osmoautotrophs. The ribbon-like fossils resemble tentacled organisms, and are thought to have fed by capturing prey. The frondose fossils resemble sea pens and other cnidarians. The trace fossils suggest that there were annelid type creatures, and the disk fossils resemble sponges. Despite these similarities, much of the identification is speculation since the fossils do not show very distinct structures. Other fossils do not resemble any known lineages.
=== Cranial leak === Cranial leaks occur in the head, and in some of these cases, CSF can leak from one side of the nose, or from the ear. Intracranial hypertension is often associated with a spontaneous cranial CSF leak, rarely reported with a spinal leak.
The most common cause of a myocardial infarction is the rupture of an atherosclerotic plaque on an artery supplying heart muscle. Plaques can become unstable, rupture, and additionally promote the formation of a blood clot that blocks the artery; this can occur in minutes. Blockage of an artery can lead to tissue death in tissue being supplied by that artery. Atherosclerotic plaques are often present for decades before they result in symptoms. The gradual buildup of cholesterol and fibrous tissue in plaques in the wall of the coronary arteries or other arteries, typically over decades, is termed atherosclerosis. Atherosclerosis is characterized by progressive inflammation of the walls of the arteries. Inflammatory cells, particularly macrophages, move into affected arterial walls. Over time, they become laden with cholesterol products, particularly LDL, and become foam cells. A cholesterol core forms as foam cells die. In response to growth factors secreted by macrophages, smooth muscle and other cells move into the plaque and act to stabilize it. A stable plaque may have a thick fibrous cap with calcification. If there is ongoing inflammation, the cap may be thin or ulcerate. Exposed to the pressure associated with blood flow, plaques, especially those with a thin lining, may rupture and trigger the formation of a blood clot (thrombus). The cholesterol crystals have been associated with plaque rupture through mechanical injury and inflammation.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.